Trials / Unknown
UnknownNCT04527224
Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia
A Phase I/Ⅱa Trial to Explore the Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell (AstroStem-V) Therapy in Patients With COVID-19 Pneumonia
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Nature Cell Co. Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, single-arm study to evaluate the safety and efficacy of Astrostem-V, allogenic adipose tissue derived mesenchymal stem cells (AdMSC), in patients with COVID-19 pneumonia. After each subject completes 12-Weeks visit (Visit 12) and the data management team confirms all individual data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AstroStem-V | Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs) |
Timeline
- Start date
- 2022-10-24
- Primary completion
- 2023-11-01
- Completion
- 2023-12-01
- First posted
- 2020-08-26
- Last updated
- 2023-01-10
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04527224. Inclusion in this directory is not an endorsement.